CD274 and adenosquamous carcinoma: Subgroup analyses found that PD-L1 was positive in 28 of 74 (37.8%) squamous cell carcinomas, 2 of 7 (28.6%) adenosquamous carcinomas, and 2 of 12 (16.7%) endocervical adenocarcinomas (45).